Compare DFLI & IBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DFLI | IBIO |
|---|---|---|
| Founded | 2020 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.0M | 50.4M |
| IPO Year | N/A | N/A |
| Metric | DFLI | IBIO |
|---|---|---|
| Price | $3.97 | $2.28 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $22.50 | $4.00 |
| AVG Volume (30 Days) | 851.1K | ★ 3.1M |
| Earning Date | 11-14-2025 | 02-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $57,783,000.00 | $500,000.00 |
| Revenue This Year | $17.85 | N/A |
| Revenue Next Year | $30.29 | $11.11 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 18.24 | ★ 185.71 |
| 52 Week Low | $1.50 | $0.56 |
| 52 Week High | $26.50 | $6.89 |
| Indicator | DFLI | IBIO |
|---|---|---|
| Relative Strength Index (RSI) | 61.74 | 55.53 |
| Support Level | $3.75 | $2.10 |
| Resistance Level | $4.55 | $2.37 |
| Average True Range (ATR) | 0.45 | 0.29 |
| MACD | -0.09 | -0.03 |
| Stochastic Oscillator | 63.14 | 41.66 |
Dragonfly Energy Holdings Corp is a manufacturer of non-toxic deep cycle lithium-ion batteries that are designed to displace lead acid batteries in a number of different storage applications and end markets including RV, marine vessel, and solar and off-grid industries, with disruptive solid-state cell technology currently under development. The company's deep cycle lithium iron phosphate ("LFP") batteries provide numerous advantages compared to incumbent products, such as lead-acid batteries. LFP batteries are non-toxic and environmentally friendly, do not rely on scarce or controversial metals, and are a cost-effective storage solution.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.